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Abstract
Tacrolimus is the key component of most contemporary immunosuppressive drug 
regimens for the prevention of transplant rejection. Area under the concentration time 
curve over 24 h (AUC0– 24) predicts efficacy, but predose (trough) tacrolimus blood 
concentration (C0) is currently used to guide dosing. In clinical or research situations 
where an estimate of AUC is required, collection of a full 24 h pharmacokinetic (PK) 
profile is cumbersome. Limited sampling strategies (LSSs) have been developed for 
some tacrolimus preparations but not for the new, extended- release, once- daily for-
mulation of tacrolimus, ENVARSUS XR. Twenty- four kidney transplant recipients 
were enrolled in this study. Twenty- four tacrolimus PK profiles were obtained over 
24 h. Multiple linear regression was used to generate LSSs with the best subset se-
lection for accurate estimation of tacrolimus AUC0– 24. The predictive performance 
of each model was assessed in the evaluation group. The correlation between actual 
and predicted AUC0– 24 was evaluated and mean percentage prediction error (MPE%), 
mean absolute percentage prediction error (MAE%), and root mean squared error 
(RMSE) were calculated for each prediction model to assess bias and precision. The 
selected LSSs were highly correlated to AUC0– 24 compared with the correlation be-
tween C0 and AUC0- 24. Two and three sampling points limited sampling strategies: 
C0, C2, and C10 provide the most reliable and effective LSS for estimation of tacroli-
mus AUC0– 24 in routine clinic use. These limited sampling models can be applied 
in therapeutic drug monitoring schemes to personalize tacrolimus dosing for kidney 
transplant recipients on treatment with extended- release tacrolimus.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Tacrolimus is a narrow therapeutic index drug with wide pharmacokinetic (PK) var-
iability between individuals. There is evidence that tacrolimus exposure based on 
blood concentration (C0) monitoring can vary extensively. Although AUC is consid-
ered the best exposure indicator related to tacrolimus clinical effects, tacrolimus C0 
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INTRODUCTION
Tacrolimus is a cornerstone of the immunosuppressive drug 
regimens used for solid organ transplantation. Tacrolimus 
has a narrow therapeutic window and its high pharmacoki-
netic (PK) variability renders dose selection challenging. To 
a certain extent, it is genetically related.1 Therefore, regular 
monitoring and adjustment of tacrolimus dose is crucial to 
prevent rejection and adverse effects associated with toxic 
drug concentrations.2 Efficacy and side effects of immuno-
suppressive drugs are highly correlated with the area under 
the concentration time curve (AUC). However, recording 
a full PK profile for every patient is not feasible in clinical 
practice.3,4 Consequently, predose trough concentration (C0) 
monitoring is the most widely used method to guide tacroli-
mus dosing in routine clinical practice. Despite the simplicity 
of this method, which provides a high correlation with AUC, 
some concerns have been raised about therapeutic drug mon-
itoring (TDM) accuracy based on C0 with tacrolimus AUC 
reported to vary by up to twofold for the same C0 concentra-
tion.5 Moreover, there are conflicting data relating tacrolimus 
C0 to clinical outcomes. Toxicity and rejection sometimes 
occur within the target range.6
In clinical or research situations where a greater degree 
of confidence in predicting the AUC than can be provided 
by C0 monitoring, limited sampling strategies (LSSs) offer a 
practical alternative to collecting full 24 h PK profiles. LSS 
include a limited number of samples, such as trough and time 
points within a short time post- dose.7 Collection of full 24 h 
PK profiles is both costly and likely to be a deterrent to sub-
ject recruitment to clinical trials.
ENVARSUS XR is an extended- release formulation of 
tacrolimus that has been licensed for routine use recently. It 
has been designed using MeltDose drug delivery technology 
to allow sustained release of the drug as it passes along the 
intestine, rather than the rapid absorption that occurs with 
immediate release twice daily tacrolimus formulations. 
extended- release tacrolimus formulation has shown equiva-
lent efficacy and safety to twice daily tacrolimus in de novo 
and stable kidney transplant recipients8,9 and to once daily 
tacrolimus (ADVAGRAF) in stable kidney transplant recipi-
ents.9 It achieves equivalent drug exposure over 24 h to once 
and twice- daily tacrolimus with at least a 30% dose reduction 
requirement and a significant decrease in tacrolimus maxi-
mum concentration (Cmax) in the blood.
10 LSSs to estimate 
AUC0– 24 have been developed for other tacrolimus prepara-
tions (Armendáriz, et al.11 2005; Mathew et al.7 2008; and 
van Boekel et al.4 2015). However, limited data are available 
for an appropriate LSS for kidney transplant recipients who 
use once- daily tacrolimus formulation, ENVARSUS XR. 
Therefore, the purpose of the study was to develop a clini-
cally precise and applicable LSS to estimate the area under 
the curve (AUC0– 24) of modified- release tacrolimus.
PATIENTS AND METHODS
Patients
A total of 24 stable kidney transplant recipients were re-
cruited for the study. All patients received a stable dose of 
twice- daily tacrolimus (ADOPORT; Sandoz Limited) or 
once- daily tacrolimus (ADVAGRAF; Astellas, Ireland) and 
no more than 5 mg prednisolone daily with either mycophe-
nolate or azathioprine as part of their immunosuppressive 
regimen. The conversion ratio target from ADOPORT or 
monitoring is the most commonly used method in routine clinical practice. There is 
no limited sampling strategy (LSS) available for kidney transplant recipients using 
extended- released tacrolimus.
WHAT QUESTION DID THIS STUDY ADDRESS?
This study assessed different LSSs for an accurate estimation of area under the con-
centration time curve over 24 h (AUC0– 24) for extended- released tacrolimus.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Tacrolimus exposure can be accurately measured using two and three sampling points 
of LSS in kidney transplant recipients using extended- released tacrolimus.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR 
TRANSLATIONAL SCIENCE?
These LSSs can be applied in therapeutic drug monitoring (TDM) schemes to per-
sonalize tacrolimus dosing in routine clinical practice for kidney transplant recipients 
receiving extended- released tacrolimus. Moreover, it can be used in PK clinical trials 
providing an accurate AUC0– 24 estimation. It also can have useful implementation in 
the new micro- sampling techniques.
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ADVAGRAF to ENVARSUS XR was 0.7 or 0.85 for sub-
jects of Black ethnicity (genetically sub- Saharan African). 
The total daily dose was given as a single dose in the morn-
ing (8:00 a.m.) during the study period with adjustment of the 
dose to maintain 24 h postdose C0 concentration in the range 
4– 9 μg/L for at least 2 weeks prior to blood sample collection 
for the 24 h PK profile. Inclusion criteria required that the 
participants were at least 18 years old and at least 12 weeks 
after transplantation. Exclusion criteria included lactose in-
tolerance and treatment with potent cytochrome P4503A and 
P- glycoprotein inducers or inhibitors.
For PK sampling, full tacrolimus AUC0– 24 with 13 blood 
samples was collected at 0 (C0), 0.5 (C0.5), 1 (C1), 1.5 (C1.5), 
2 (C2), 2.5 (C2.5), 3 (C3), 4 (C4), 6 (C6), 8 (C8), 10 (C10), 12 
(C12), and 24 (C24) h after morning tacrolimus dose. Five mL 
of blood was collected at each time point into EDTA tubes 
after at least 2 weeks of stable tacrolimus dose. Whole blood 
samples were stored at −20°C until analyzed. The study 
protocol was approved by National Research Ethics Service 
Committee (REC Number: 18/LO/0524) and all study partic-
ipants provided written informed consent.
Analytical methods
Tacrolimus blood samples were measured using a validated 
liquid chromatography- tandem mass spectrometry (LC- MS/
MS) method with a lower limit of quantitation (LLOQ) of 
0.25 µg/L. The calibration range was 1– 50 µg/L with a cor-
relation coefficient (r) of 0.998. Tacrolimus was extracted 
from 50 µL blood using liquid- liquid extraction. Ascomycin 
(50 µL, ~50 µg/L) was used as internal standard. The extrac-
tion procedure was performed using 1  ml of precipitating 
solution (500 ml zinc sulphate solution (25 g/L); 200 mL of 
acetonitrile; and 300 ml methanol). After mixing and centrif-
ugation, the supernatant was decanted into clean tubes with 
100 µL of 0.1 mol/L sodium hydroxide and 2 ml of Methyl- 
tert- butyl ether. After mixing and centrifugation, the organic 
solvent was evaporated to dryness, reconstituted with 250 µL 
of 80% methanol, and 10 µL injected into the LC- MS/MS. 
An API4000 triple quadruple mass spectrometer equipped 
with a turbo- ion spray was used in positive mode. The transi-
tions selected were m/z 821.5/768.5 for tacrolimus and m/z 
809.5/756.5 for ascomycin. Nitrogen was used as the colli-
sion gas. Gas settings in mL/min were: collision gas: 8, cur-
tain gas: 10, ion source gas 1: 35, and ion source gas 2: 30. 
Ion spray voltage: 5500 V, and temperature: 450°C. Entrance 
potential (EP), collision energy (CE), and collision cell exit 
potential (CXP) in voltage were 10, 29, and 18 V, respec-
tively. The dwell times were set at 300 msec. Declustering 
potential (DP) was 81 for tacrolimus and 76 for ascomycin. 
Chromatographic separation was performed using Agilent 
HPLC and Alltima C18, 5 µm, 150 × 2.1 mm column (Merck 
[BDH] Limited, Poole, Dorset, England) at a temperature of 
65°C. The mobile phase was pumped isocratically at a flow 
rate of 0.4 ml/min and consisted of a mixture of mobile phase 
A (methanol) and mobile phase B (de- ionized water +5 ml/L 
2  M ammonium acetate) at a ratio of 82:18, respectively. 
Tacrolimus and internal standard were eluted at retention 
times 2.9 and 2.8, respectively.
Pharmacokinetic parameters
The area under the whole blood concentration- time curve 
(AUC) was calculated using the linear trapezoidal method. 
The peak plasma concentration (Cmax) and the time to 
achieve Cmax (Tmax) were obtained from direct visual inspec-
tion of plasma concentration versus time curves. Descriptive 
statistics for variables were reported as mean ± SD or median 
(range). A correlation coefficient test was used to assess the 
correlation between C0 and AUC0– 24.
LSS development and validation
Limited sampling strategy techniques aim to predict the 
AUC0– 24 using an equation and a small number of blood sam-
ples collected at specific times. The evaluation for each LSS 
method was carried out by repeated cross validation. The 
evaluation method included the following steps:
a. The data set was repeatedly and randomly divided into 
two subsets. One was used to fit the model between 
tacrolimus AUC0– 24 and each of the created linear re-
gression models. This group was called the training 
group (n  =  15) and the other group was used to test 
the model; the testing or evaluation group (n  =  9). 
This process was repeated 50 times. Each time tacroli-
mus concentrations at the selected sampling time points 
for the 15 PK profiles in the training group were used 
to fit to the created linear regression models to tacroli-
mus AUC0– 24 using multiple linear regression analysis. 
The equations produced were as follows:
Where β1– βn are the regression coefficients, I is the intercept, n 
is the nominal sample collection time, and c1– cn are tacrolimus 
concentrations measured at times 1- n for each of the regression 
models.
b. Best subsets regression was applied to derive the possi-
ble limited sampling equations. The best equations were 
selected for each of the 1, 2, and 3 time sampling point 
AUC0−24 = 1C1 + 2C2 +…+ nCn + I
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equations within 10 h after drug administration depending 
on the coefficient of determination (r2).
c. The linear regression models obtained from the train-
ing group were used to estimate and validate tacrolimus 
AUC0– 24 for the remaining 9 PK profiles in the evaluation 
group. Additionally, a limited sampling model for C0 was 
used in the validation.
d. The predictive performances of these models were then 
assessed. The predicted AUC0– 24 calculated using each 
limited sampling strategy was compared to actual AUC0– 24 
calculated using the linear trapezoidal method.
Statistical analysis
The Anderson- Darling test was used to assess the normality 
of the data distribution. Descriptive statistics were performed 
using mean ± SD or median (range). Linear regression analy-
sis was used to compare the predicted AUC0– 24 from each 
model against the actual AUC0– 24.
12 Prediction error (PE) 
was calculated for each patient using the equation:
The potential predictions bias was evaluated using mean 
percentage prediction error (MPE%). MPE% was determined 
using the equation:
The precision of the predictions was assessed using mean 
absolute percentage prediction error (MAE%) and root mean 
squared prediction error (RMSE) for each individual model. 
MAE% and RMSE was calculated using the following 
equations:
Statistics were carried out using 95% confidence inter-
vals.13 Bland– Altman plots were used to analyze the agree-
ment between predicted AUC0– 24 and actual AUC0– 24. A 
Pearson correlation coefficient test was used to assess the 
correlation between predicted AUC0– 24 and actual AUC0– 24. 
The acceptable limits for the prediction model evaluation 
were less than or equal to 5%, less than or equal to 10%, and 
less than or equal to 15% for MPE%, MAE%, and RMSE, 
respectively.14,15
Statistical analysis was performed using software pack-
age Minitab 19 (Minitab software, USA) and Excel 2010 
(Microsoft).
PE = predicted AUC0−24 − actual AUC0−24.
MPE%=Mean [100%× (predicted AUC0−24
−actual AUC0−24)∕actual AUC0−24].




mean (predicted AUC0−24 − actual AUC0−24)
2




Age, years, mean, ± SD 52.75 ± 11.77
Weight, kg, mean, ± SD 76.91 ± 16.95
Height, m, mean, ± SD 1.68 ± 0.08
Time after transplantation, years, mean, ± SD 7.07 ± 4.97
eGFR, ml/min/1.73 m2*, mean, ± SD 52.38 ± 19.37
Serum creatinine, µmol/L, median (range) 133.5 (65– 393)
Serum albumin, g/L, mean, ± SD 38.29 ± 3.42
Hematocrit, mean, ± SD 0.39 ± 0.06
Diabetes mellitus, n 5 (21%)
Immunosuppression at baseline
Tacrolimus, n
Adoport/Advagraf 14 (58%)/10 (42%)
Steroids, n 9 (38%)
Mycophenolate mofetil, n 11 (46%)









Original renal disease, n (%)
IgA nephropathy 5 (21%)




Granulomatosis with polyangiitis 1 (4%)
Pyelonephritis 1 (4%)
Polycystic kidneys 1 (4%)
Congenital renal dysplasia 1 (4%)
ESRD secondary to bilateral nephrectomies 1 (4%)
Uncertain etiology 1 (4%)
Abbreviations: eGFR, estimated glomerular filtration rate; ESRD, endstage renal 
disease.
aThe eGFR was determined using Chronic Kidney Disease Epidemiology 
Collaboration calculation.
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RESULTS
Baseline characteristics
Of 100 stable kidney transplant patients who were screened, 
21 were considered not eligible for participation, 40 de-
clined to participate, and 14 did not respond to follow- up 
calls. Therefore, 25 patients were recruited for the study 
and 24 participants completed a full PK profile. One patient 
was discontinued from the study due to a moderate side 
effect (diarrhea). Reported or noted adverse events were 
diarrhea,1 serum creatinine fluctuation,2 and high blood 
pressure.1
The characteristics of the 24 patients included in the 
study are shown in Table  1. All transplant recipients were 
at least 5 months post- transplantation. The mean age of re-
cipients was 53  ±  12  years. Concomitant immunosuppres-
sion included prednisolone (n = 9), mycophenolate mofetil 
(n = 11), and azathioprine (n = 8). At baseline, 14 patients 
(58%) were receiving ADOPORT and 10 patients (42%) 
were receiving ADVAGRAF. The median daily dose of 
ADVAGRAF was 4.50 mg (range 1.50– 10.00), whereas the 
median daily dose of ADOPORT was 3.50 mg (range 1.00– 
30.00). Regarding self- declared ethnic origin, 15 patients 
were from White backgrounds, 4 Asian, 4 Black, and 1 other 
ethnic background.
Pharmacokinetic parameters
PK parameters of extended- release tacrolimus are sum-
marized in Table  2. All patients’ tacrolimus blood con-
centrations were within the therapeutic window with C0 of 
5– 8 µg/L. C0 was checked and adjusted before carrying out 
tacrolimus PK profiles for patient’s safety. The median daily 
dose was 2.73  mg (range 0.75– 25.5). The geometric mean 
(95% confidence interval) for Cmax, AUC0– 24, and C0 were 
12.32  µg/L (10.77– 13.87), 192.29  µg*h/L (173.72– 210.86) 
and 5.79 µg/L (5.10– 6.49), respectively.
Limited sampling strategy equations 
for tacrolimus
Regression models with various sampling time points and 
their combinations were generated for AUC0– 24 predic-
tion using the concentration- time data of the training set. 
Five predictive models consisting of one to three sampling 
points with the coefficient of determination (r2) are shown in 
Table 3. The commonly used trough C0 to predict tacrolimus 
exposure (AUC0– 24) provided r
2 value of 0.70. One sampling 
time point model at 10 h yielded an acceptable r2 value of 
0.91. Limited sampling models based on two sampling points 
at 0 and 10 h, and 2 and 10 h displayed r2 values of 0.92 and 
T A B L E  2  Summary of tacrolimus PK parameters (n = 24)
Variable Mean SD CV% Median Range, min– max
Cmax, µg/L 12.32 3.67 29.76 11.64 6.95– 22.07
Tmax, h 5.15 2.24 43.59 5.00 2.00– 8.00
AUC0– 24, µg*h/L 192.29 43.98 22.87 191.88 138.78– 305.75
Dose, mg 4.53 5.15 113.69 2.73 0.75– 25.50
C0, µg/L 5.79 1.65 28.41 5.33 3.10– 9.49
C0.5, µg/L 5.93 1.36 22.85 5.76 4.27– 8.89
C1, µg/L 6.81 1.94 28.50 6.51 4.02– 10.64
C1.5, µg/L 7.51 2.79 37.08 6.90 4.06– 15.49
C2, µg/L 8.27 3.31 40.01 7.44 4.11– 16.23
C2.5, µg/L 9.07 3.81 42.05 8.03 4.68– 22.07
C3, µg/L 9.78 3.61 36.91 9.03 4.85– 18.82
C4, µg/L 10.24 3.66 35.73 9.51 5.94– 18.08
C6, µg/L 10.65 2.97 27.87 10.73 6.02– 16.51
C8, µg/L 9.74 2.54 26.08 9.37 6.00– 15.04
C10, µg/L 8.85 2.29 25.92 8.53 5.68– 15.44
C12, µg/L 8.09 2.07 25.56 7.71 5.54– 13.48
C24, µg/L 5.71 1.40 24.50 5.32 3.60– 9.30
Abbreviations: AUC0– 24, area under the time- concentration curve in a 24 h period; C0 to C24, the concentrations at 0 to 24 h; Cmax, maximum concentration; CV%, 
coefficient of variation; Tmax, time for reaching maximum concentration.
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0.97, respectively. Limited sampling model using the time 
points at 0, 2, and 10 h provided the highest r2 value.
There were no relevant effects of hematocrit, dose, sex, 
ethnicity, time after transplantation, or co- administration of 
steroids, on correlation of determination (r2).
Predictive performance of limited sampling 
methods for tacrolimus
Table 4 summarizes the predictive performance of each of 
the limited sampling strategies. Bias and precision were as-
sessed using the evaluation set (n = 9). All equations showed 
a better correlation with AUC0– 24 than C0. The limited sam-
pling model that incorporated C0 measurements (model 1) 
demonstrated the lowest correlation of all the limited sam-
pling models (r2 = 0.84). It resulted in an acceptable bias 
(MPE%, −0.12) and the highest imprecision (MAE% 12.43% 
and RMSE 27.59%) compared with the other LSS models. 
A strong correlation was found using the LSS equation in-
cluded C10 (model 2) for estimation of AUC0– 24 (r
2 = 0.95). 
MPE%, MAE5 and RMSE were within the acceptable limits. 
Two sampling point models using C0 and C10 measurements 
(model 3), and C2 and C10 measurements (model 4) were ac-
ceptable and predictive of tacrolimus AUC0– 24 based on bias 
and precision assessment. The performance of model 5 with 
sampling time points at 0, 2, and 10 h displayed the least 
bias and the most precise estimation to all equations (r2 = 
0.99, MPE% −0.13, MAE%, 3.44, and RMSE 7.94). Figure 1 
shows the Bland- Atman plots for models2- 5 that illustrates 
the bias and precision for each model. Limits of agreement 
(LOA) included 95% of the differences between predicted and 
actual tacrolimus AUC0– 24. There were no significant differ-
ences between tacrolimus measurements using these models. 
Moreover, there was no consistent direction of the bias pat-
tern with predicted AUC0– 24 values were above and below the 
actual values. Figure 2 demonstrates the correlations between 
predicted AUC0– 24 and actual AUC0– 24 for each participant 
using LSS models within the acceptable limits. Models 4 and 
















































































































































































































































































































































































































































































































































































































T A B L E  3  Limited sampling strategies to predict tacrolimus 
AUC0– 24 in adult kidney transplant recipients
Model Equation r2
Model 1 AUC0– 24 = 64.73 + 21.62 T0 0.70
Model 2 AUC0– 24 = 31.55 + 18.18 T10 0.91
Model 3 AUC0– 24 = 26.38 + 5.67 T0 + 15.02 T10 0.92
Model 4 AUC0– 24 = 21.95 + 3.90 T2 + 15.59 T10 0.97
Model 5 AUC0– 24 = 20.26 + 3.19 T0 + 3.63 T2 + 
14.01 T10
0.98
Abbreviation: AUC0– 24, area under the time- concentration curve in a 24 h 
period.
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DISCUSSION
To our knowledge, this study is the first to be reported de-
veloping and validating an LSS using regression equations 
to predict the AUC0– 24 of the extended- released tacrolimus 
formulation in adult kidney transplant recipients. In general, 
C0 is routinely used in tacrolimus dose adjustment in clinical 
practice. However, this study showed a moderate correlation 
between C0 and AUC0– 24 (r
2 = 0.84) and it did not meet the 
precision criteria. This result revealed that the LSS model 
including the single time point C0 is a suboptimal marker for 
prediction of tacrolimus AUC0– 24, although it is probably 
sufficiently accurate for most routine clinical situations. The 
prediction limited sampling formula for the AUC0– 24 using 
the single C10 time point gave the highest correlation with 
the actual AUC0– 24 (r
2 = 0.95). However, therapeutic drug 
monitoring using C10 with morning dosing would be chal-
lenging to apply in clinical practice. LSS using C0 and C10 
showed a slight improvement in the model correlation (r2 = 
0.96) compared with using C10 alone. Another LSS model 
F I G U R E  1  Bland- Altman plot comparing the differences and averages of the AUCActual and AUCPredicted with the center line represents the 
mean difference and the red lines represent limits of agreement (LOA) with 95% confidence intervals around the mean difference. AUC0– 24, area 
under the concentration time curve over 24 h
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including C2 and C10 represented a good improvement in the 
model performance, including bias and precision compared 
with using C0 and C10.
This model provided more reliable and accurate estima-
tion of the tacrolimus AUC0– 24. When LSS model with three 
sample points (C0, C2, and C10) were used, the correlation 
between the predicted and actual AUC0– 24 (r
2) was almost 
equal to the correlation obtained using two points LSS model 
(C2 and C10). Therefore, LSS with 2 time points 2 and 10 h 
would provide sufficient accuracy for prediction of tacroli-
mus AUC0– 24 in clinical practice where a true measure of 
AUC is required or in clinical trials. The two or three sample 
point models would be useful to minimize the number of 
samples required for tacrolimus PK profile from 10 to 13 
samples to 2 or 3 samples which is more convenient and 
cost- effective.
This study has some limitations. This is a relatively small 
sample size. A further limitation is that concentration time 
points indicated by the models may not be accurately reflec-
tive with a relatively small shift in the collection time. In 
addition, this method is suitable for stable kidney transplant 
recipients more than 3  months post- transplantation. More 
studies are required for patients with varying renal func-
tion and tacrolimus concentrations particularly in the first 
F I G U R E  2  The correlation between predicted AUC0– 24 and actual AUC0– 24. AUC0– 24, area under the concentration time curve over 24 h
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3  months post- transplant when more critical estimation of 
tacrolimus concentrations is required.
In conclusion, the validated LSS algorithms from this study 
could prove a very useful tool in therapeutic drug monitoring 
for prediction of the systemic exposure of extended release tac-
rolimus in clinical practice. Moreover, they could be used in 
PK clinical trials providing a practical and precise approach 
to estimate the AUC. It may also be useful in implementation 
of microsampling techniques as an alternative easier and more 
patient- friendly method than the current conventional methods 
for accurate measurement of tacrolimus, which requires a veni-
puncture and over 1 ml of blood for each sample drawn.
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